

REMARKS

The following is in response to the Official Action dated 12/03/2007, which was indicated for response within 1 month. In the Action, then pending claims 1-3 and 7-11 were subject to a restriction requirement, as follows:

Group I, claims 1-3, and 7-11, drawn to compounds, compositions and methods of use, of the compounds of formula (I) where p is 1.

Group II, claims 1-3, and 7-11, drawn to compounds, compositions and methods of use, of the compounds of formula (I) where p is 2.

Applicant hereby elects without traverse, the invention directed to Group I.

In this amendment, claim 1 has been amended, claims 2, 3 and 7-11 have been cancelled, and new claims 12-29 have been added. Thus, claims 1, 12-29 are now pending for examination. All claims are directed to species where p is 1.

Applicant files this amendment without prejudice, specifically reserving the right to file subsequent divisional, continuation or continuation in part applications on any subject matter cancelled from the claims in this amendment, or for which basis is provided in the specification.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Favorable consideration of the application is hereby requested. If any minor matters exist precluding allowance of this application, the examiner is requested to contact the applicant's representative at the number below.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicant
Registration No. 39,009

Date: January 3, 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8022
Facsimile: 919-483-7988